Forecast

There is no analyst data available for this company.

News Go to news feed

SCHOTT Pharma posts surprisingly strong first half despite weak demand

Supplier SCHOTT Pharma increased group sales in the first half to the end of March by around 1% to €488.1 million. EBITDA remained almost at last year’s level at €129.8 million, despite a one-off impairment on customer-specific glass syringes. The result was driven by continued strong demand for sterile vials and carpules; CEO Christian Mias described the outcome as on plan. CFO Reinhard Mayer highlighted lower receivables and a markedly higher free cash flow; the annual targets were confirmed. » More on finanzen.net
SCHOTT Pharma starts the year strongly and confirms guidance

SCHOTT Pharma reported a surprisingly strong, profitable first quarter thanks to rising demand for high-margin, high-value solutions such as ready-to-use cartridges and specialty vials. Currency-adjusted revenue rose by about 5% to €240.2 million, EBITDA grew by over 11% to €65.2 million, and the EBITDA margin was 27.1%. Management confirms the revenue and earnings guidance for 2026 and expects currency-adjusted full-year revenue growth of 2–5% and an operating margin of around 27%. Group CEO Andreas Reisse will hand over leadership in May to Christian Mias. » More on finanzen.net
SCHOTT Pharma board member Mayer buys 2,999 shares at €14.93

BaFin reported an insider trade on 18 December 2025: board member Mayer, Reinhard, acquired 2,999 SCHOTT Pharma shares at €14.93 each. In the FSE session the price subsequently fell to €14.70. SCHOTT Pharma has a market capitalization of around €2.21 billion and 150,614,608 tradable shares. » More on finanzen.net